{
  "ticker": "IMCR",
  "company_name": "Immunocore Holdings plc",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT03973333",
      "title": "Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab",
      "status": "WITHDRAWN",
      "phase": "PHASE1, PHASE2",
      "condition": "Select Advanced Solid Tumors",
      "start_date": "2019-05-17",
      "completion_date": "2023-09-25",
      "enrollment": 0,
      "sponsor": "Immunocore Ltd"
    },
    {
      "nct_id": "NCT03515551",
      "title": "Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers",
      "status": "TERMINATED",
      "phase": "PHASE1, PHASE2",
      "condition": "Select Advanced Solid Tumors",
      "start_date": "2018-06-15",
      "completion_date": "2021-05-10",
      "enrollment": 0,
      "sponsor": "Immunocore Ltd"
    },
    {
      "nct_id": "NCT04960891",
      "title": "A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp",
      "status": "AVAILABLE",
      "phase": "",
      "condition": "Uveal Melanoma",
      "start_date": "",
      "completion_date": "",
      "enrollment": 0,
      "sponsor": "Immunocore Ltd"
    },
    {
      "nct_id": "NCT02535078",
      "title": "Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma",
      "status": "WITHDRAWN",
      "phase": "PHASE1, PHASE2",
      "condition": "Malignant Melanoma",
      "start_date": "2015-11",
      "completion_date": "2023-09-06",
      "enrollment": 0,
      "sponsor": "Immunocore Ltd"
    },
    {
      "nct_id": "NCT01211262",
      "title": "Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Malignant Melanoma",
      "start_date": "2010-09-28",
      "completion_date": "2017-02-16",
      "enrollment": 0,
      "sponsor": "Immunocore Ltd"
    },
    {
      "nct_id": "NCT05867056",
      "title": "Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection",
      "status": "WITHDRAWN",
      "phase": "PHASE1",
      "condition": "Hepatitis B, Chronic",
      "start_date": "2020-08-12",
      "completion_date": "2024-12-15",
      "enrollment": 0,
      "sponsor": "Immunocore Ltd"
    },
    {
      "nct_id": "NCT07156136",
      "title": "Study of IMC-P115C in Advanced PRAME-Positive Cancers",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "PRAME Positive, Cancer, HLA-A*02:01-positive",
      "start_date": "2024-11-07",
      "completion_date": "2029-08-30",
      "enrollment": 0,
      "sponsor": "Immunocore Ltd"
    },
    {
      "nct_id": "NCT03070392",
      "title": "Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Uveal Melanoma",
      "start_date": "2017-10-16",
      "completion_date": "2025-12",
      "enrollment": 0,
      "sponsor": "Immunocore Ltd"
    },
    {
      "nct_id": "NCT06627244",
      "title": "Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver",
      "start_date": "2025-02-14",
      "completion_date": "2031-02-17",
      "enrollment": 0,
      "sponsor": "University of Miami"
    },
    {
      "nct_id": "NCT02570308",
      "title": "A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Uveal Melanoma",
      "start_date": "2016-02-29",
      "completion_date": "2022-10-17",
      "enrollment": 0,
      "sponsor": "Immunocore Ltd"
    }
  ],
  "summary": {
    "total_trials": 18,
    "by_phase": {
      "PHASE1, PHASE2": 6,
      "": 1,
      "PHASE1": 3,
      "PHASE2": 5,
      "PHASE3": 3
    },
    "by_status": {
      "WITHDRAWN": 3,
      "TERMINATED": 2,
      "AVAILABLE": 1,
      "COMPLETED": 2,
      "RECRUITING": 8,
      "ACTIVE_NOT_RECRUITING": 2
    },
    "active_trials": 10,
    "completed_trials": 2,
    "conditions": [
      "Advanced Melanoma",
      "Cancer, HLA-A*02:01-positive",
      "Hepatitis B, Chronic",
      "Malignant Melanoma",
      "Melanoma (Skin), Melanoma, Uveal",
      "Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver",
      "PRAME Positive, Cancer, HLA-A*02:01-positive",
      "Select Advanced Solid Tumors",
      "Uveal Melanoma"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:18:58.988143",
    "search_query": "Immunocore Holdings plc",
    "url": "https://clinicaltrials.gov/search?term=Immunocore+Holdings+plc"
  }
}